Boosted Flow Cytometry for Active Latent TB Discrimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for tuberculosis (TB) are inadequate for accurately distinguishing between active and latent TB infections, which hampers effective treatment and control of the disease, especially in low- and middle-income countries.
Innovation Solution
The development of a method using boosted flow cytometry and boosted ELISPOT technology to assay antigen-specific T cell responses by determining the levels of specific cytokines and chemokines related to T-cell polarization profiles, specifically for Mycobacterium tuberculosis antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods (smear microscopy) are used, then the testing process is simple and accessible, but the detection sensitivity is low (only 50-60 percent of cases detected)
Solution Approach 1:
The patent replaces conventional mechanical microscopy methods with flow cytometry and ELISPOT technologies that detect cytokine profiles and T-cell responses. This substitution enables detection of latent TB infections and active disease states through immunological markers rather than direct visual identification, achieving higher sensitivity (detecting up to 90% of cases) while maintaining operational feasibility through standardized laboratory protocols.
Solution Approach 2:
The patent changes the detection parameters from direct visualization of bacterial morphology to measurement of immunological parameters (cytokine concentrations, T-cell frequencies, polarization profiles). By measuring IFN-γ, IL-2, IL-4, IL-10, IL-17, and other cytokines along with T-cell activation markers, the system achieves superior detection sensitivity for both active and latent TB while providing additional diagnostic differentiation capabilities.
2Measurement precision
If advanced diagnostic methods (Xpert MTB/RIF test) are used, then detection speed and sensitivity are improved, but the test cost increases and portability is reduced
Solution Approach 1:
The patent segments the diagnostic assessment into multiple independent measurement components: flow cytometry for cytokine profiling, ELISPOT for T-cell frequency detection, and polarization analysis. This segmentation allows each component to be optimized independently and performed using standard laboratory equipment rather than requiring expensive integrated platforms, reducing overall cost while maintaining high sensitivity through combined measurements.
Solution Approach 2:
The patent creates a universal diagnostic platform that can detect both active and latent TB infections, identify disease stage, and characterize immune response profiles using the same core technologies (flow cytometry and ELISPOT). This multi-functional approach eliminates the need for separate expensive specialized tests for different diagnostic purposes, reducing overall system cost while enhancing comprehensive detection capability.
3Loss of information
If current diagnostic tools are used, then the testing infrastructure is simple, but the ability to discriminate between active and latent TB is insufficient
Solution Approach 1:
The patent adds multiple diagnostic dimensions simultaneously: cytokine concentration measurements, T-cell frequency quantification, polarization profile characterization, and response kinetics analysis. By measuring multiple immunological parameters across different time points and using multiple detection modalities (flow cytometry + ELISPOT), the system achieves comprehensive differentiation between active and latent TB while providing detailed immune status information that guides treatment decisions.
Solution Approach 2:
The patent uses cytokine profiles and T-cell polarization states as intermediary markers that mediate the detection of disease state. Rather than directly visualizing bacteria or relying on single-marker tests, the system measures the immunological intermediary responses (IFN-γ/IL-10 ratios, IL-17 production, T-cell activation markers) that serve as proxies for disease activity and stage, enabling accurate discrimination without requiring complex direct visualization capabilities.
Data Source
AI summary
The present invention relates to a method for assaying antigen-specific T-cell responses through boosted flow cytometry and boosted ELISPOT technologies that are based on the use of specific combinations of monoclonal antibodies to stain simultaneously cytokines that in their combination identify specific T-cell polarization profiles. The method allows the identification of Tfc CD8+ T cell responses unrecognized so far.